This edition of Quick Notes features announcements of a Recursion and Exscientia merger, Boehringer Ingelheim acquisition of Nerio Therapeutics, BioNTech’s decision to discontinue working with Genmab on acasunlimab, the sale of Mallinckrodt’s Therakos business, expansion of Daiichi Sankyo’s and Merck’s collaboration agreement, and Sangamo’s development deal with Genentech.